Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer

被引:63
作者
Tong, Charles C. L. [1 ]
Kao, Johnny [2 ]
Sikora, Andrew G. [1 ,3 ,4 ,5 ]
机构
[1] Mt Sinai Sch Med, Dept Otolaryngol Head & Neck Surg, New York, NY USA
[2] Good Samaritan Hosp, Med Ctr, Dept Radiat Oncol, New York, NY USA
[3] Mt Sinai Sch Med, Dept Dermatol, New York, NY USA
[4] Mt Sinai Sch Med, Dept Immunol, New York, NY USA
[5] Tisch Canc Inst, New York, NY USA
关键词
Head and neck squamous cell carcinoma (HNSCC); Immune suppression; Immunotherapy; Tumor-infiltrating lymphocytes; Myeloid-derived suppressive cells (MDSC); Regulatory T cells; Tumor-mediated immunosuppression; Tumor immunology; SQUAMOUS-CELL CARCINOMA; HUMAN-PAPILLOMAVIRUS VACCINES; SUPPRESSOR-CELLS; PHASE-II; PROGNOSTIC VALUE; MYELOID CELLS; T-CELLS; MACROPHAGE INFILTRATION; INHIBITION; DIFFERENTIATION;
D O I
10.1007/s12026-012-8306-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The estimated annual incidence of oral cavity and pharyngeal cancer is 39,000 in the United States and 260,000 cases worldwide. Despite significant advances in surgery, chemotherapy and radiotherapy, the 5-year survival rate for locally advanced head and neck tumors remains at 50 %. With further intensification of existing treatment limited by the already significant morbidity of multi-modality treatment, there is a clear need for novel therapeutic strategies [1]. Accumulating evidence suggests that the tumor microenvironment of head and neck squamous cell carcinoma (HNSCC) is highly immunosuppressive, mediated by soluble and cell-associated inhibitory mediators and recruitment of host immunosuppressive cells. Thus, understanding and reversing the specific mechanisms underlying tumor-mediated immunosuppression in HNSCC is an important approach to generating an effective antitumor immune response, either as a component of immune-based therapy or as a complement to conventional treatment approaches. This article outlines significant immune-suppressive mechanisms in the HNSCC tumor microenvironment and potential approaches to enhancing the antitumor immune response.
引用
收藏
页码:266 / 274
页数:9
相关论文
共 95 条
  • [1] Ifosfamide in the treatment of head and neck cancer
    Airoldi, M
    Cortesina, G
    Giordano, C
    Pedani, F
    Bumma, C
    [J]. ONCOLOGY, 2003, 65 : 37 - 43
  • [2] T Cell-Tumor Interaction Directs the Development of Immunotherapies in Head and Neck Cancer
    Albers, A. E.
    Strauss, L.
    Liao, T.
    Hoffmann, T. K.
    Kaufmann, A. M.
    [J]. CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2010,
  • [3] Almand B, 2000, CLIN CANCER RES, V6, P1755
  • [4] Validation of Genetic Sequence Variants as Prognostic Factors in Early-Stage Head and Neck Squamous Cell Cancer Survival
    Azad, Abul Kalam
    Bairati, Isabelle
    Samson, Elodie
    Cheng, Dangxiao
    Mirshams, Maryam
    Qiu, Xin
    Savas, Sevtap
    Waldron, John
    Wang, Changshu
    Goldstein, David
    Xu, Wei
    Meyer, Francois
    Liu, Geoffrey
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (01) : 196 - 206
  • [5] Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers
    Badoual, C
    Hans, S
    Rodriguez, J
    Peyrard, S
    Klein, C
    Agueznay, NE
    Mosseri, V
    Laccourreye, O
    Bruneval, P
    Fridman, WH
    Brasnu, DF
    Tartour, E
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (02) : 465 - 472
  • [6] T regulatory type 1 cells in squamous cell carcinoma of the head and neck: Mechanisms of suppression and expansion in advanced disease
    Bergmann, Christoph
    Strauss, Laura
    Wang, Yun
    Szczepanski, Miroslaw J.
    Lang, Stephan
    Johnson, Jonas T.
    Whiteside, Theresa L.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (12) : 3706 - 3715
  • [7] Bian Y., 2011, Oncogene
  • [8] Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck
    Boucek, Jan
    Mrkvan, Tomas
    Chovanec, Martin
    Kuchar, Martin
    Betka, Jaroslav
    Boucek, Vladimir
    Hladikova, Marie
    Betka, Jan
    Eckschlager, Tomas
    Rihova, Blanka
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2010, 14 (1-2) : 426 - 433
  • [9] Brandwein-Gensler A, 2005, AM J SURG PATHOL, V29, P167
  • [10] Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells
    Bronte, V
    Apolloni, E
    Cabrelle, A
    Ronca, R
    Serafini, P
    Zamboni, P
    Restifo, NP
    Zanovello, P
    [J]. BLOOD, 2000, 96 (12) : 3838 - 3846